Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPCTED)

• Drug Name: PMID23521020C7k Drug Info
• Synonyms: GTPL8164; BDBM50430865; ZINC95592818

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 71624791
  TTD Drug ID: DMPCTED

Molecule-Related Drug Atlas

Drug(s) Targeting Epithelial discoidin domain receptor 1 (DDR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9567304, Compound N-9	DMCGUNB	N. A.	N. A.	Patented	[2]
US9156852, 83	DM1K5T0	N. A.	N. A.	Patented	[3]
US9695118, 8	DMAD3VL	N. A.	N. A.	Patented	[4]
NG7	DMW1PL7	N. A.	N. A.	Patented	[5]
US9567304, Compound F-54	DM81MV6	N. A.	N. A.	Patented	[2]
VAPBGCRAUJRZPO-UHFFFAOYSA-N	DMOVEZF	N. A.	N. A.	Patented	[4]
BDBM50080408	DM4I829	N. A.	N. A.	Patented	[2]
US9695118, 4	DMZF3AQ	N. A.	N. A.	Patented	[4]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[7]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[8]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[9]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[10]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[11]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[12]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epithelial discoidin domain receptor 1 (DDR1)	TTI1FPZ	DDR1_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[1]

References

• [1] Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95.
• [2] Quinazolinedione derivative. US9567304.
• [3] Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852.
• [4] Benzamide derivative. US9695118.
• [5] Fused 2-aminothiazole compounds. US8765747.
• [6] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [7] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [8] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [13] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [14] National Cancer Institute Drug Dictionary (drug id 452042).